TY - JOUR AU - Wu, Shu-ta AU - Fowler, Anthony J. AU - Garmon, Corey B. AU - Fessler, Adam B. AU - Ogle, Joshua D. AU - Grover, Kajal R. AU - Allen, Bailey C. AU - Williams, Chandra D. AU - Zhou, Ru AU - Yazdanifar, Mahboubeh AU - Ogle, Craig A. AU - Mukherjee, Pinku PY - 2018 DA - 2018/04/23 TI - Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles JO - BMC Cancer SP - 457 VL - 18 IS - 1 AB - Pancreatic ductal adenocarcinoma (PDA) remains the most aggressive cancers with a 5-year survival below 10%. Systemic delivery of chemotherapy drugs has severe side effects in patients with PDA and does not significantly improve overall survival rate. It is highly desirable to advance the therapeutic efficacy of chemotherapeutic drugs by targeting their delivery and increasing accumulation at the tumor site. MUC1 is a membrane-tethered glycoprotein that is aberrantly overexpressed in > 80% of PDA thus making it an attractive antigenic target. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-018-4393-7 DO - 10.1186/s12885-018-4393-7 ID - Wu2018 ER -